Page 1

Pulmonary Vascular Input Impedance is a Combined Measure of

Pulmonary Vascular Resistance and Stiffness and Predicts

Clinical Outcomes Better than PVR Alone in Pediatric Patients

with Pulmonary Hypertension

Kendall S. Hunter, PhD1, Po-Feng Lee, MSc2, Craig J. Lanning, BSc1, D. Dunbar Ivy, MD1,

K. Scott Kirby, RDCS1, Lori R. Claussen, BSN, RN1, K. Chen Chan, MD1, and Robin

Shandas, PhD1,3

1 Department of Pediatric Cardiology, University of Colorado Health Sciences Center, 1056 E.

19th Ave, Denver, CO 80218

2 Department of Bioengineering, Texas A&M University, College Station, TX 77843

3 Department of Mechanical Engineering, University of Colorado at Boulder, Boulder, CO

80309-0427

Abstract

Background—Pulmonary vascular resistance (PVR) is the current standard for evaluating

reactivity in children with pulmonary arterial hypertension (PAH). However, PVR measures only

the mean component of right ventricular afterload and neglects pulsatile effects. We recently

developed and validated an method to measure pulmonary vascular input impedance, which

revealed excellent correlation between the zero-harmonic impedance value and PVR, and

suggested a correlation between higher harmonic impedance values and pulmonary vascular

stiffness (PVS). Here we show that input impedance can be measured routinely and easily in the

catheterization laboratory, that impedance provides PVR and PVS from a single measurement, and

that impedance is a better predictor of disease outcomes compared to PVR.

Methods—Pressure and velocity waveforms within the main PA were measured during right-

heart catheterization of patients with normal PA hemodynamics (n=14) and those with PAH

undergoing reactivity evaluation (49 subjects; 95 conditions). A correction factor needed to

transform velocity into flow was obtained by calibrating against cardiac output. Input impedance

was obtained off-line by dividing Fourier-transformed pressure and flow waveforms.

Results—Exceptional correlation was found between the indexed zero harmonic of impedance

and indexed PVR (y=1.095·x+1.381, R2=0.9620). Additionally, the modulus sum of the first two

harmonics of impedance was found to best correlate with indexed pulse pressure over stroke

volume (PP/SV) (y=13.39·x-0.8058, R2=0.7962). Amongst a subset of PAH patients (n=25),

cumulative logistic regression between outcomes to total indexed impedance was better

(RL2=0.4012) than between outcomes and indexed PVR (RL2=0.3131).

© 2007 Mosby, Inc. All rights reserved.

Address for Correspondence: Robin Shandas, Ph.D., Cardiovascular Flow Research Laboratory, Division of Cardiology, 1056 E. 19th.

Ave., B-100, The Children’s Hospital, Denver, CO 80218, shandas.robin@tchden.org, Phone: (303) 837 2586, Fax: (303) 860 4056.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our

customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of

the resulting proof before it is published in its final citable form. Please note that during the production process errors may be

discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

NIH Public Access

Author Manuscript

Am Heart J. Author manuscript; available in PMC 2011 July 20.

Published in final edited form as:

Am Heart J. 2008 January ; 155(1): 166–174. doi:10.1016/j.ahj.2007.08.014.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 2

Conclusions—Input impedance can be consistently and easily obtained from PW Doppler and a

single catheter pressure measurement, provides comprehensive characterization of the main

components of RV afterload, and better predicts patient outcomes compared to PVR alone.

Keywords

hypertension; pulmonary; pulmonary heart disease; pediatrics; echocardiography; hemodynamics

Introduction

The hemodynamic status of children with pulmonary arterial hypertension (PAH) is

currently assessed through invasive measurement of pulmonary vascular resistance (PVR),

which is the ratio of the mean pulmonary artery pressure drop across the pulmonary

microvasculature to cardiac output. Because PVR is computed with mean values, it

quantifies only the steady-state resistance presented to the heart, and ignores the dynamic

impact of stiffness (or compliance) on the circuit [1–3]. In contrast, both static (PVR) and

dynamic, i.e. pulmonary vascular stiffness (PVS) information is provided by the pulmonary

vascular input impedance. Impedance is analogous to the ratio of the arterial pressure

waveform to the blood flow waveform over an entire cardiac cycle, and thus includes both

mean and pulse data. Here, we measure pressure and flow at the entrance to the main

pulmonary artery, which yields the input impedance of the whole pulmonary vasculature. In

an earlier study on a smaller number of patients we showed that this input impedance is both

easily measured during a routine catheterization study and provides information on both

steady and dynamic components of right ventricular afterload [4]. The importance of

including dynamic (stiffness) components in evaluation of PAH has since been confirmed as

a better predictor of mortality [5].

Because impedance includes both resistive and stiffness components of right ventricular

(RV) afterload, it should represent a simple-to-obtain measure of global pulmonary vascular

function in patients with pulmonary hypertension. Further, we hypothesize that impedance,

as a better measure of RV afterload, will be a superior predictor of patient outcomes

compared to PVR alone. The goals of this study were: 1) measure pulmonary vascular input

impedance in a large pediatric clinical population (63 subjects, 109 conditions); 2) determine

an appropriate correction factor to convert Doppler velocity measurement into flow for

impedance calculations; 3) correlate harmonic values of impedance against

hemodynamically measured PVR and PVS; and 4) examine capabilities of impedance and

PVR to predict 1-year outcomes for a sub-set of patients (n=25).

Methods

Clinical Study

Patient Selection—After institutional review board approval and informed consent and

assent had been obtained, data were obtained during routine cardiac catheterization that is

part of the regular evaluation and treatment of these subjects at the Children’s Hospital in

Denver, CO. The patient population was divided into two groups. Group 1 studies were

conducted after intervention to correct congenital heart defects (8 PDA, 6 ASD), had normal

MPA pressures, and were considered the control group (14 patients; median age = 2yrs,

range = 1.66–16yrs; 10 females). The remainder of patients (49 patients, 95 reactivity

conditions; median age = 3yrs, range = 0.25–17yrs; 18 females) suffered from PAH. 31

patients in the hypertensive group underwent tests for acute changes in hemodynamic

parameters (reactivity) with the administration of oxygen, nitric oxide, or other therapeutic

agents (Epoprostenol, Diltiazem, Sidenafil, lloprost). The majority of these 31 patients

underwent only a single reactivity study, but some patients underwent as many as four such

Hunter et al. Page 2

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 3

tests. A summary of patient characteristics, calculated at the patient level (n=63) is provided

in Table 1; additionally, the quartiles of age and MPAP are plotted in Figures 1A & B.

Clinical Data Acquisition—Pressure measurements were made with standard fluid-filled

catheters (Transpac IV, Abbot Critical Care Systems) within the main PA. PW Doppler

velocity measurements were taken with a commercial ultrasound scanner (Vivid 5, GE

Medical Systems Inc) from a parasternal short axis view within the midpoint of the main

PA. Two dimensional echo and color Doppler was used to align the ultrasound beamline

parallel to the main flow direction within the PA. We estimate minimal errors due to

ultrasound beam angulation (< 5°). Cardiac output was measured by Fick’s method with

measured oxygen consumption in cases where intracardiac shunts were in place and by

thermodilution otherwise. Correct temporal alignment of the velocity and pressure signals

was assured by storing the latter in digitized form on the auxiliary input of the ultrasound

scanner simultaneously with PW Doppler (i.e. velocity) data. Measurements were made for

16 seconds for each patient; this typically encompassed 20 cardiac cycles. By definition

impedance requires temporal histories of pressure and flow; here flow time-histories are

calculated from Doppler velocity measurements, as explained below.

Data Analysis

MPA midline velocity time-histories were obtained semi-automatically from the recorded

PW Doppler signals through the use of a custom edge-detection method to determine the

appropriate envelope velocity in each PW Doppler time slice. Figure 2 shows the interface

used for this method; in the figure, a red line superimposed upon the PW Doppler data on

the main (upper) axes is the computed the time-history, while the lower axes show both the

AUX1 trace (pressure, in yellow) and the ECG trace (in blue) used to separate cardiac

cycles. The method is referred to as “semi-automatic” in that user input was occasionally

needed to remove velocity spikes due to noise and/or valve clicks from the time-history.

From each velocity time-history [V (t)] and mean cardiac output measurement(CO), the

corresponding flow time-history Q(t) was then computed as

(1)

in which the constant area correction factor Acorr is found from

(2)

where V̄ is the mean velocity computed from the midline velocity time-history. This

calculation relies on the assumption that the spatial profile of the velocity is nearly constant

across the vessel (i.e. “top-hat” profile); this is not unreasonable since typical Womersley

numbers found in the MPA are much greater than 1.0, indicating flat profiles [6].

Computational fluid dynamics studies from our group have confirmed that velocity profiles

within the main PA are indeed flat over the pulsatile cycle [7]. The pressure and calculated

velocity time-histories were then separated into individual cardiac cycles (n > 20) based on

ECG gating. A discrete Fourier transform (DFT) was then performed on the pressure and

flow time-histories for each cycle, yielding values for their spectral moduli and phase at

discrete multiples (harmonics) of the cardiac cycle frequency. The input impedance modulus

was readily obtained as

Hunter et al.Page 3

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 4

(3)

in which ω is the discrete frequency of interest. Two parameters were extracted from the

impedance data: the zero harmonic impedance value (Z0), which should correlate with distal

vascular resistance, and the sum of the impedance values from the first two harmonics

(Z1+Z2), which should correlate to the pulmonary vascular stiffness. Although higher

harmonics of impedance (> 2nd) also quantify stiffness and may contain additional

information such as reflection strength, their modulus values contained sufficiently high

uncertainty to preclude inclusion for statistical analysis or clinical relevance. Additionally,

right ventricular power calculations [8] indicate that these higher harmonics carry negligible

power and thus may be safely neglected in consideration of afterload.

Clinical follow-up was available for twenty-five patients (median age 4 yrs, range 0.25–19

years; 11 males). The majority of these patients had a septal defect closure (n=18); three had

idiopathic PAH, two had undergone repair of a cognitive diaphragmatic hernia, and two had

PDA closure. Median follow-up time was 12 months (range 1–33 months) after the initial

assessment or procedure. Mean values of indexed impedance sum (= BSA · (Z0 + Z1 + Z2)),

abbreviated hereafter as ZsumI, and PVRI (i.e., indexed PVR) over the baseline and

challenge conditions were computed for each patient. Additionally, patients were placed into

one of three numerical outcomes categories based on World Health Organization scores pre

and post treatment [9]. A numerical score of 1 indicated improvement (change of ≥ 1

functional classes for the better, e.g. change in WHO grade from IV to II or III to II); a score

of 2 indicated moderate worsening (change of one functional class for the worse); and a

score of 3 indicated significant worsening (change of ≥ 2 functional classes for the worse) or

death. Nine patients showed no change in WHO scores; these patients were placed into one

of the three categories above based on their constant WHO classification. For example, a

patient classified as WHO grade I and who did not show change in this grade during the

follow-up examination was placed in outcomes category 1, while a constant WHO grade II

or III was placed in outcomes category 2, etc. Generally, the categories are intended to

represent patients who show excellent response to initial treatment (category 1), those who

are unlikely to respond to the current standard of care may be candidates for more extensive

early therapy (category 2), and those who are at great risk and need urgent attention

(category 3).

Statistical Analysis

Linear regressions are obtained via the method of least-squares from the pooled data under

the assumption that multiple observations of a single patient (i.e. reactivity conditions) may

be considered independent degrees of freedom. This assumption is reasonable when there is

a substantial change (taken here as >20%) in the hemodynamic state due to the

administration of therapeutic agents. Because inclusion of acute non-responder data –

defined throughout the paper as data that show less than a 20% acute change in either Z0 or

Z1+Z2 due to reactivity challenges – have the potential to skew regressions, we examine the

impact of these cases in more detail by comparing regressions obtained with and without

them. Coefficients of determination for the regressions are calculated according to standard

procedure (see, e.g. [10]). For the clinical follow-up analysis, single values for each patient

were obtained in ZsumI and PVRI by averaging over all reactivity conditions, and an

outcomes factor was assigned as noted above. Cumulative logistic regression between these

parameters and the ordinal outcomes categories was performed with the PROC LOGISTIC

procedure in SAS (SAS Institute Inc, Cary, NC) and goodness-of-fit statistics were

computed as described in [11]. Finally, uncertainties for each measurement were obtained as

described previously [4].

Hunter et al. Page 4

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 5

Results

Patients in the normotensive group (I) had normal pulmonary pressures (MPAP = 16.9±4.7

mmHg), whereas the other group (II) displayed PAH (MPAP = 37.3±18.7 mmHg, baseline

condition); this difference was statistically significant (p<0.0001). The mean cardiac indices

of the normotensive and hypertensive groups, respectively, 6.7±6.4 L/(min·m2) and 4.1±2.3

L/(min·m2), and their mean heart rates, 105±17.9bpm and 109±28.0bpm, were not

significantly different.

Obtaining impedance for each patient added no more than 5 minutes to each study.

Representative impedance curves for each Group are shown in Figures 3A and 3B. As seen

in the figures, the hypertensive patients typically displayed both larger values of Z0,

indicating higher PVR [1–4,8], and larger values of the first several harmonics of

impedance. Differences in Z0 and Z1+Z2 between the normotensive and hypertensive

patients were significant (p< 0.05). Quartiles of PVR, Z0, and Z1+Z2 are seen in Figures 1C,

D, & E. In accord with our previous study, excellent agreement between indexed Z0 and

hemodynamically measured indexed PVR was found (y= 1.095·x+1.381, R2=0.9620; Figure

4). Three correlations were examined for the higher harmonics of impedance, listed in order

from best of fit to poorest: Z1+Z2 compared to 1) indexed pulse pressure divided by stroke

volume, or hemodynamically measured pulmonary vascular stiffness (y= 13.39·x-0.8058,

R2=0.7962; Figure 5A); 2) hemodynamically measured PVRI (y= 0.8528·x+3.593,

R2=0.2997; Figure 5B); and 3) mean pulmonary artery pressure (y= 0.1525·x+3.536,

R2=0.1307; Figure 5C).

The regressions above were examined to quantify the impact of acute non-responders. For

the indexed Z0 –vs– PVRI regression, this imposed the removal of 19 data sets that were

non-responsive in indexed Z0. The new regression (63 patients, 90 reactivity conditions) has

the same slope (to three significant digits) and an intercept 4.3% larger than the original.

This change in intercept (0.058 mm Hg/(L/min)) is less than 0.3% of the total range of

indexed Z0 data. For the PVS regressions 20 data sets were removed due to non-response; of

interest is the overlap of 13 cases that were non-responsive in Z0 and Z1+Z2, leaving 6 cases

that responded in Z0 only and 7 cases that responded in Z1+Z2 only. The resulting reduced

data set for Z1+Z2 (63 patients, 89 reactivity conditions) yielded regressions with slopes

differing by −3.7%, −5.9%, and 14.6%, respectively, from the originals shown in Figure 4.

The intercept values of all three regressions changed by as much as 24.2% in absolute value;

however such a change represents less than 0.5% of the entire range of Z1+Z2.

Acorr was calculated from measured cardiac output and linearly correlated against body

surface area, patient age in months, mean pulmonary artery pressure, pulse pressure, and

cardiac output, with both bivariate and multivariate methods. BSA (y=2.142·x+0.3128,

R2=0.4263) and CO (y=0.3632·x+0.5064, R2=0.6520) displayed respectable correlation;

additional regressions of Acorr against age, MPAP, and pulse pressure found lesser fits in

each case (R2=0.3181, R2=0.0885, R2=0.0530, respectively). Notable multivariate linear

regressions of Acorr against these parameters produced little additional increase in goodness-

of-fit, except one that considered BSA and CO [Acorr=0.2161–0.7402(BSA)+0.2977(CO),

R2=0.6817]. These indicate that BSA may be used to determine the area correction factor to

convert Doppler-measured velocity to flow for impedance calculations in future studies.

For the 25 patients for whom clinical follow-up data was examined, indexed impedance sum

and PVRI were regressed against outcomes category to determine outcomes likelihood (i.e.

probability); Table 2 contains regression parameters and their statistical significance, while

Table 3 lists means & standard deviations for each outcomes category. Both models more

than satisfied the proportional odds assumption (p>0.3 for both). Figure 6 shows likelihood

Hunter et al. Page 5

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 6

curves for each outcomes category & normalized predictor; black curves correspond to

ZsumI and red curves correspond to PVRI, while solid, dashed, and dot-dashed lines are

used to represent categories 1, 2, and 3, respectively. We see that ZsumI has a higher

probability of a category 2 outcome (66.1% probability to 52.8%) over a broader normalized

range (40.1% of range to 28.6%), while having nearly identical odds of improvement (i.e.

category 1) at low parameter values and of worsening (category 3) at high parameter values.

Thus, ZsumI is better at differentiating between the three categories. This is borne out by

goodness-of-fit statistic, which for ZsumI and outcomes is better (RL2=0.4012) than for

PVRI and outcomes (RL2=0.3131). We also examined the ability of indexed PP/SV to

predict outcomes; interestingly, its goodness-of-fit was worse (RL2=0.2112) than both

ZsumI and PVRI.

Discussion

Evaluation of PVR and reactivity in PVR are currently the primary means of determining

the severity of pediatric pulmonary hypertension, classifying patients pre-operatively, and

determining appropriate therapy for PAH [12]. Although PVR is a dominant component of

RV afterload, it is not the only component. Pulmonary vascular stiffness can play a

significant role in maintaining low RV afterload in healthy patients and conversely,

exacerbating afterload in patients with pulmonary hypertension. Vascular input impedance,

which theoretically includes both resistance and stiffness components, should thus be the

best global measure of RV afterload, and consequently should also provide a better means of

predicting outcomes than PVR alone [1–4,8]. Although impedance is not a new concept, its

application to clinically relevant diagnostics has been hampered by the lack of an easy-to-

implement method to obtain it. We have shown [4] using in vitro and preliminary clinical

data the utility of a method combining measurement of main PA pressure with computation

of instantaneous PA flow using Doppler velocity measurements to obtain impedance easily

during routine cardiac catheterization of patients with PAH. This study extends this prior

work significantly by: 1) studying a larger number of patients; 2) providing explicit

correlations between Z0 and PVR, and between Z1+Z2 and hemodynamically measured

pulmonary vascular stiffness; 3) correlating the correction factor, required to “correct”

Doppler-measured velocities and obtain instantaneous flow, to facilitate future use of this

method; and 4) obtaining regressions of outcomes against impedance and PVR to show the

clinical utility of impedance measurement. Results show impedance is a highly promising

clinically realizable measurement for comprehensively evaluating pulmonary vascular

function in patients with PAH.

Measurement of impedance possesses several advantages over the traditionally derived

hemodynamic variables (PVR, PP/SV) obtained through right-heart catheterization. First, it

enables quantification of both system resistance and stiffness with a single measurement,

which is important given the relatively moderate correlations that have been found between

reactivity in PVR and clinical outcomes [12]. Because impedance is measured at a single

position in the vasculature, it also does not require the measurement of wedge pressure,

which may be problematic in certain patients. Through use of the presented correlation Acorr

with BSA, or with imaging measurements of MPA area, measurement of instantaneous flow

with or without measured cardiac output becomes much simpler. Note that if cardiac output

were available it would only add confidence to the instantaneous flow measurement

obtained from Doppler since the correction factor can be explicitly calculated for each

patient and condition. Finally, the measurement of impedance adds roughly 5 minutes to the

catheterization study, primarily for the Doppler measurement.

The importance of vascular stiffness in determining ventricular afterload is becoming

increasingly recognized in hypertension management strategies in the pulmonary circulation

Hunter et al.Page 6

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 7

[5] and on the systemic side [13–16]. Links between arterial stiffening and systemic

hypertension are well established [17,18]. Here we demonstrate the same on the pulmonary

side, and additionally establish that impedance well-quantifies stiffness in the clinical

situation, as Z1+Z2 is clearly a good correlate of indexed pulse pressure over stroke volume

(BSA·PP/SV), or pulmonary vascular stiffness (PVS). Of the three hemodynamics variables

with which correlation was attempted, PVS is the best constitutive measure in that it

expresses the ratio of a given change in a kinetic or force variable (pulse pressure) over a

resulting change in a kinematic or displacement variable (normalized vascular displacement,

SV/BSA). We have explored other constitutive measures such as the dynamic compliance

[19]; although promising as well, these require measurement of both pressure and arterial

wall displacements. PVRI is purely indicative of viscous flow losses, whereas the mean

pulmonary pressure is simply a kinetic measure, without any link to a resultant

displacement; hence it is no surprise that both have lesser correlations with Z1+Z2. We note

that stiffness as represented by Z1+Z2, unlike resistance and the other clinical measures it is

compared to, is already independent of body mass; thus it is not normalized with BSA prior

to comparison.

There are several ways this method may be used clinically. For example, this study provides

some guidance on how to classify indexed impedance sum values, similar to how PVRI

values are used clinically. From the outcomes analysis (Fig 6, Table 3) we see that, in

general, ZsumI < 10 indicates a relatively healthy pulmonary circulation and appear to

predict good to moderately good outcomes. ZsumI > 18 appears to indicate high RV

afterloads and predict poorer outcomes. Based purely on comparison to PVRI, we calculate

that ZsumI predicts a PVRI of > 3 m2 mm Hg/(L/min) with an 87.2% sensitivity and an

91.7% specificity; thus pre-operative evaluation may alternatively use a ZsumI value of 8 as

indicative of onset of PAH (= PVRI > 3) and of 18 as a means of generally classifying

patients into outcomes categories. Although the outcomes analysis is preliminary in nature

(n=25), it reveals that inclusion of stiffness effects enhances outcomes prediction in terms of

goodness-of-fit and changes the form of outcomes probabilities for patients in poor health.

Future studies will investigate Z0 and Z1+Z2 as independent predictors of outcomes (i.e.

multivariate regression); for the current small data set, such models were not statistically

significant and thus were not included. Impedance may also provide a means of

distinguishing effects of novel therapies, especially those that may affect upstream vascular

tone and therefore alter pulmonary vascular stiffness versus those that affect downstream

vascular tone and therefore alter pulmonary vascular resistance. We continue to perform

impedance studies in our catheterization laboratory and will continue to expand our database

of impedance correlations to further cement these findings.

There are several limitations that must be acknowledged. Impedance values at higher

harmonics (beyond the 2nd) were not included due to their higher levels of measurement

uncertainty and minuscule power content. In certain patients, this may underestimate true

RV afterload since wave reflections, which typically manifest at higher harmonics, are not

taken into account. The use of a constant area factor does affect the calculation of flow,

although previous in-vitro studies on compliant models [4] suggest only a moderate impact

on the harmonics of impedance. The regression for the area correction factor may need to be

further refined for reactivity testing since we found as much as 20% variation in this factor

due to reactivity. This could be done through additional secondary and/or tertiary correlates,

such as the systolic acceleration time or the ratio of this time to the ejection time, which may

influence the velocity profile and correspondingly the area correction factor. Other methods

such as MRI could also be used to measure instantaneous flow directly without any need for

correction factors. We did not examine reactivity in impedance as another potential predictor

of outcomes, nor did we evaluate how impedance changes with the administration of

different therapies; this work is ongoing. We note that exclusion of the non-responder data –

Hunter et al.Page 7

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 8

which may represent dependent observations – was seen to have a minor impact on the

regressions performed. Thus, inclusion of such data does not appear to invalidate the

statistical analysis. We note that the Doppler data was acquired at 100Hz, which provides

useful frequency information up to 50Hz; additionally, the fluid-filled catheters used have

been shown to have flat frequency response up to 15Hz. Thus, we may have confidence in

the harmonics of impedance up to at least the sixth harmonic (for a heart rate of 120BPM),

and to higher harmonics for lower heart rates.

In summary, we have shown in a relatively large pediatric patient population that pulmonary

vascular input impedance provides a comprehensive yet easy-to-obtain measure of RV

afterload in that it includes both resistance and vascular stiffness effects. Using a sub-set of

patients where we also obtained outcomes, we also show impedance as a better and more

significant predictor of clinical outcomes than PVR alone.

Acknowledgments

This project was supported by in part by grants from the National Institutes of Health (R01-HL067393, T32-

HL072738, SCCOR-HL081506, K24-HL084923, and M01-RR0069). KSH would like to thank Craig E. Weinberg,

PhD of BDC Laboratories, Golden, CO, for our many helpful discussions regarding impedance computation, and

Joseph A. Albietz, MD, of the University of Colorado at Denver and Health Science Center for our helpful

discussions of disease outcomes.

References

1. Caro CG, McDonald DA. The Relation of Pulsatile Pressure and Flow in the Pulmonary Vascular

Bed. J Physiol. 1961; 157(3):426–453. [PubMed: 13690903]

2. Patel DJ, DeFreitas FM, Fry DL. Hydraulic Input Impedance to Aorta and Pulmonary Artery in

Dogs. J Appl Physiol. 1963; 18(1):134–140. [PubMed: 13941792]

3. Bergel DH, Milnor WR. Pulmonary Vascular Impedance in the Dog. Circ Res. 1965; 16(5):401–

415. [PubMed: 14289149]

4. Weinberg C, Hertzberg J, Valdes-Cruz LM, Shandas R. Extraction of pulmonary vascular

compliance, PVR and RV work from single-pressure and Doppler flow measurements in children

with pulmonary hypertension -- a new method for evaluating reactivity: In vitro and clinical studies.

Circulation. 2004; 110(7):2609–2617. [PubMed: 15492299]

5. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of Pulmonary Arterial

Capacitance and Mortality in Idiopathic Pulmonary Arterial Hypertension. J Am Coll Cardiol.

47(4):799–803. [PubMed: 16487848]

6. Milnor, WR. Hemodynamics. Williams & Winkins; Baltimore, MD: 1982.

7. Hunter KS, Lanning CJ, Zhang Y, Garg R, Ivy DD, Shandas R. Simulations of Congenital Defect

Closure and Drug Reactivity Testing in Patient-Specific Models of the Pediatric Pulmonary

Vasculature: A 3-D Numerical Study with Fluid-Structure Interaction. J Biomech Engr. 2006;

128(4):564–572.

8. Milnor WR, Bergel DH, Bargainer JD. Hydraulic Power Associated with Pulmonary Blood Flow

and its Relation to Heart Rate. Circ Res. 1966; 19(3):467–480. [PubMed: 5925148]

9. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and

differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43(12):40S–

47S. [PubMed: 15194177]

10. Johnson, RA.; Wichern, DW. Applied Multivariate Statistical Analysis. Vol. Chapter 7. Prentice

Hall; Upper Saddle River, NJ: 1998.

11. Menard, S. Applied Logistic Regression Analysis. 2. Sage Publications; Thousand Oaks, CA:

2002.

12. Rashid A, Ivy DD. Severe Pediatric Pulmonary Hypertension. New Management Strategies. Arch

Dis Child. 2005; 90(1):92–98. [PubMed: 15613526]

Hunter et al.Page 8

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 9

13. Domanski MJ, Mitchell GF, Norman JE, Exner DV, Pitt B, Pfeffer MA. Independent prognostic

information provided by sphygmomanometrically determined pulse pressure and mean arterial

pressure in patients with left ventricular dysfunction. Journal of the American College of

Cardiology. 1999; 33:951–958. [PubMed: 10091821]

14. Mitchell GF, Moye LA, Braunwald E, et al. Sphygmomanometrically determined pulse pressure is

a powerful independent predictor of recurrent events after myocardial infarction in patients with

impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement.

Circulation. 1997; 96:4254–4260. [PubMed: 9416890]

15. St John Sutton M. Aortic stiffness: a predictor of acute coronary events? European Heart Journal.

2000; 21:342–344. [PubMed: 10666343]

16. Stefanadis C, Dernellis J, Tsiamis E, et al. Aortic stiffness as a risk factor for recurrent acute

coronary events in patients with ischaemic heart disease. European Heart Journal. 2000; 21:390–

396. [PubMed: 10666353]

17. Safar ME, London GM, Asmar R, Frohlich ED. Recent Advances on Large Arteries in

Hypertension. Hypertension. 1998; 32(1):156–161. [PubMed: 9674653]

18. Stefanadis C, Dernellis J, Vlachopoulos C, et al. Aortic Function in Arterial Hypertension

Determined by Pressure-Diameter Relation: Effects of Diltiazem. Circulation. 1997; 96(6):1853–

1858. [PubMed: 9323072]

19. Dyer KL, Lanning CJ, Das BB, Ivy DD, Shandas R. Development and validation of a non-invasive

color M-mode tissue Doppler imaging technique for measuring pulmonary artery compliance: in

vitro and clinical studies. J Am Soc Echo. 2006; 19(4):403–412.

Hunter et al.Page 9

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 10

Figure 1.

Quartiles of A) age, B) mean pulmonary artery pressure (MPAP), C) pulmonary vascular

resistance (PVR), D) 0th harmonic of impedance (Z0), and E) higher-harmonic sum of

impedance (Z1+Z2).

Hunter et al. Page 10

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 11

Figure 2.

Graphical user interface for semi-automatic impedance computation. At center top is

transient PW-Doppler data with an overlain computed envelope trace; at center bottom, the

corresponding AUX1 (pressure) and ECG signals in yellow and blue, respectively.

Hunter et al.Page 11

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 12

Hunter et al.Page 12

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 13

Figure 3.

Typical impedance curves from A) Group I and B) Group II patients. Diagnoses: Patient 1,

ASD, secundum, device closure; Patient 2, PDA coil embolization, minimal residual

shunting; Patients 3-4, PDA coil embolization, no residual shunting; Patient 10, secondary

PAH, ASD, secundum + A-P Collateral arteries; Patient 14, secondary PAH, Down’s

Syndrome, ASD device closure; Patient 31, primary PAH; Patient 41, secondary PAH, ASD,

secundum.

Hunter et al. Page 13

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 14

Figure 4.

Indexed Z0 –vs– clinically measured indexed pulmonary vascular resistance (PVRI) for all

subjects (63 patients; 109 reactivity conditions).

Hunter et al.Page 14

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Page 15

Hunter et al.Page 15

Am Heart J. Author manuscript; available in PMC 2011 July 20.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript